Real‐World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add‐On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70247 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Rachita Dhurat und 10 weiteren Autor:innen. Beteiligte Einrichtung: RD Clinic, Mumbai, India. Hauptthemen laut MEDLINE: Alopecia, Minoxidil, Hair. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Androgenetic alopecia (AGA) is a common age‐related hair loss condition influenced by genetics and androgen activity.
Aim
This study evaluated the safety and efficacy of Cuticapil Stem Hair Serum in improving hair loss in AGA patients.
Method
This multicenter, prospective, observational study assessed the real‐world efficacy and safety of Cuticapil Stem Hair Serum in patients with androgenetic alopecia. A total of 60 subjects were evaluated, with the Cuticapil and Standard of Care groups compared using the Mann–Whitney and Wilcoxon signed‐rank tests. Key assessments included the hair pull test, global photographic analysis, and hair shedding count. No adverse events were reported, reinforcing the serum's favorable safety profile.
Result
The Cuticapil + SoC treatment group consistently showed higher mean ranks across multiple parameters compared to the SoC‐only group. The addition of Cuticapil Serum to SoC significantly reduced hair shedding ( p = 0.0220). In the Hair Pull Test, the Cuticapil + SoC group had a lower mean rank (26.97) than SoC alone (34.03) ( p = 0.0196), indicating greater efficacy. Global photography analysis showed a higher mean rank of 36.13 in the Cuticapil + SoC group compared to 24.87 in the SoC group ( p = 0.0057), further supporting its effectiveness.
Conclusion
Cuticapil Stem Hair Serum, when used in addition to standard care, significantly enhances hair growth and reduces hair fall in patients with mild to moderate Androgenetic Alopecia and Female Pattern Hair Loss. It showed superior results in promoting hair growth, reducing shedding, improving hair density, appearance, and managing hair loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RD Clinic, Mumbai, India.
- Torrent Pharmaceuticals Ltd, Ahmedabad, India.
- Dr. Ganjoo's Skin and Cosmetology Centre, New Delhi, India.
- Mira Derm Redefining Skin Care, New Delhi, India.
- Asia Institute of Hair Transplant, Pune, India.
- Dr. Vaidys's Skin and Laser Clinic, Pune, India.
ORCID-Profile: Rachita Dhurat, Girish R Kulkarni
Zitieren
APA
Dhurat, R., Kulkarni, G. R., Ganjoo, A., Agarwal, M., Kumari, P., Vaidya, P., Gupta, S., Savant, S., Nair, R., Agarwal, M., & Agarwal, P. (2025). Real‐World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add‐On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70247
Vancouver
Dhurat R, Kulkarni GR, Ganjoo A, Agarwal M, Kumari P, Vaidya P, et al. Real‐World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add‐On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70247
BibTeX
@article{Dhurat2025,
author = {Dhurat, Rachita and Kulkarni, Girish R and Ganjoo, Anil and Agarwal, Manjul and Kumari, Pradeep and Vaidya, Pradyuman and Gupta, Sumit and Savant, Shankar and Nair, Rathish and Agarwal, Mahima and Agarwal, Pankhuri},
title = {Real‐World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add‐On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70247}
}
EUVIMED